<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>ULTRASAL-ER- salicylic acid solution </strong><br>Elorac, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-1"></a><p></p>
<h1>Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution: Package Insert</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR TOPICAL USE ONLY.</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-1.2"></a><p></p>
<h2>DESCRIPTION
</h2>
<p class="First">UltraSal-ER is a topical preparation containing 28.5% salicylic acid extended release in a proprietary film-forming virucidal solution composed of acrylates copolymer, butyl acetate, carthamus tinctorius seed oil, cocamidopropyl dimethylamine, ethylhexylglycerin, isopropyl alcohol, isopropyl-metacresol, olea europaea fruit oil, phenic acid, phenoxyethanol, polysorbate 80, polyvinyl butyral, trimethyl pentanyl diisobutyrate, and water. The pharmacologic activity of UltraSal-ER is generally attributed to the keratolytic activity of salicylic acid, which is incorporated into a polyacrylic, film-forming virucidal solution designed to cover the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> without the need for a bandage. The structural formula of salicylic acid is:</p>
<div class="Figure">
<a name="f01"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-1.3"></a><p></p>
<h2>CLINICAL PHARMACOLOGY</h2>
<p class="First">Although the exact mode of action for salicylic acid in the treatment of <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> is unknown, its activity appears to be associated with its keratolytic action, which results in mechanical removal of epidermal cells infected with <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> viruses.  UltraSal-ER incorporates a unique patented extended release form of salicylic acid that provides for enhanced release of salicylic acid for over 24 hours.</p>
<p>The virucidal complex incorporated into UltraSal-ER’s proprietary solution is designed to help reduce risk of reinfection at the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> site, as well as prevent viral contamination of the product under normal usage.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1.4"></a><p></p>
<h2>INDICATIONS AND USAGE
</h2>
<p class="First">UltraSal-ER is indicated for the topical treatment and removal of common <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> and plantar <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-1.5"></a><p></p>
<h2>CONTRAINDICATIONS
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or impaired blood circulation should not use UltraSal-ER. UltraSal-ER also should not be used on moles, birthmarks, and unusual <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> with hair growing from them, or <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> on the face.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s5"></a><a name="section-1.6"></a><p></p>
<h2>PRECAUTIONS</h2>
<p class="First">UltraSal-ER is for external use only. Do not permit UltraSal-ER to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. UltraSal-ER should not be allowed to contact normal skin surrounding the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> site, since localized irritation may occur. Treatment should be discontinued if excessive irritation occurs.</p>
<p>UltraSal-ER is flammable. Keep away from fire or flame. Keep bottle tightly capped when not in use.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-1.7"></a><p></p>
<h2>ADVERSE REACTIONS
</h2>
<p class="First">A localized irritant reaction may occur if Ultrasal-ER is applied to the normal skin surrounding the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span>.  Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> site when treatment is resumed.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-1.8"></a><p></p>
<h2>DOSAGE AND ADMINISTRATION</h2>
<p class="First">Prior to applying UltraSal-ER, soak <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> in warm water for five minutes. Remove any loose tissue by gently rubbing with a washcloth, emery board, or pumice stone. Dry the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> site thoroughly. Using the brush applicator supplied, apply UltraSal-ER twice to the entire <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> surface, allowing the first application to dry before applying the second. Continue treatment once or twice a day as directed by your healthcare provider. Be careful not to apply to surrounding skin.</p>
<p>Clinically visible improvement normally occurs during the first or second week of therapy. Resolution may be expected after four to six weeks of UltraSal-ER use, though some <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> may take longer to remove.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s8"></a><a name="section-1.9"></a><p></p>
<h2>HOW SUPPLIED
</h2>
<p class="First">UltraSal-ER is supplied in 10 mL amber bottles with a brush applicator (NDC 42783-323-10).</p>
<p>Store at 15° to 30°C (59° to 86°F).</p>
<p>Manufactured for:</p>
<p>Elorac, Inc.</p>
<p>Vernon Hills, IL 60061</p>
<p>U.S. Patent No. 6,979,440</p>
<p>Additional Patent Pending</p>
<p>© 2014 Elorac, Inc.</p>
<p>1/2014</p>
<p>211909</p>
</div>
<div class="Section" data-sectionCode="68498-5">
<a name="s9"></a><a name="section-1.10"></a><p></p>
<h2>PATIENT INSTRUCTIONS</h2>
<p class="First">Your health care provider has prescribed UltraSal-ER, a topical prescription preparation for the treatment of common <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> and plantar <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>. In order for UltraSal-ER to work properly and to ensure maximum benefit, the following instructions should be followed carefully. Of course, as with any medication, always consult your health care provider if you experience any <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or unexpected reactions.</p>
<p><a name="f04"></a><img alt="ultrasal-5-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-04.jpg"></p>
<p><span class="Bold">STEP 1</span></p>
<p>WASH</p>
<ul class="Disc">
<li>Soak <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> area in warm water for about 5 minutes.</li>
<li>Remove any loose tissue using a washcloth, emery board, or pumice stone.</li>
<li>Dry thoroughly.</li>
</ul>
<p><a name="f05"></a><img alt="ultrasal-5-05" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-05.jpg"></p>
<p><span class="Bold">STEP 2</span></p>
<p>BRUSH</p>
<ul class="Disc">
<li>Using the brush applicator supplied, apply twice to entire <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> surface, allowing the first application to dry before applying the second.</li>
<li>Be careful not to apply to surrounding skin.</li>
<li>Leave UltraSal-ER on <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> area after it dries.</li>
</ul>
<p>Repeat Step 1 and Step 2 once or twice daily as advised by the health care provider.</p>
<p><a name="f06"></a><img alt="ultrasal-5-06" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-06.jpg"></p>
<p>Clinically visible improvement will normally occur during the first or second week of therapy.  Resolution may be expected after four to six weeks of UltraSal-ER use, though some <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> may take longer to remove.</p>
<p><a name="f07"></a><img alt="ultrasal-5-07" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-07.jpg"></p>
<p>Vernon Hills, IL  60061</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s10"></a><a name="section-2"></a><p></p>
<h1>Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution:  Container Label Principal Display Panel</h1>
<p class="First">NDC 42783-323-10</p>
<p>Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution</p>
<p>1/3 fl. oz. (10 mL)</p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="ultrasal-5-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s11"></a><a name="section-3"></a><p></p>
<h1>Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution: Carton Label Principal Display Panel</h1>
<p class="First">NDC 42783-323-10</p>
<p>Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution</p>
<p>1/3 fl. oz. (10 mL)</p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="ultrasal-5-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5&amp;name=ultrasal-5-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRASAL-ER 		
					</strong><br><span class="contentTableReg">salicylic acid solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42783-323</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>salicylic acid</strong> (salicylic acid) </td>
<td class="formItem">salicylic acid</td>
<td class="formItem">285 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42783-323-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">01/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Elorac, Inc.
							(832590009)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Elorac, Inc. (832590009)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>16ec022e-c61b-4146-8128-fb3f588a0270</div>
<div>Set id: a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5</div>
<div>Version: 2</div>
<div>Effective Time: 20140805</div>
</div>
</div> <div class="DistributorName">Elorac, Inc.</div></p>
</body></html>
